Kah Hui Yap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kah Hui Yap has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Shen-Yang Lim
Division of Neurology, Department of Medicine Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia
4 shared publications - Juen Kiem Tan
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
3 shared publications - Ai Huey Tan
Division of Neurology, Department of Medicine Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia
2 shared publications Alwin Ru Kiet Wong
2 shared publications- Anis Nadhirah Khairul Anuar
Department of Physiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
2 shared publications - Ching Soong Khoo
Department of Medicine, Faculty of Medicine Universiti Kebangsaan Malaysia Kuala Lumpur Malaysia
2 shared publications
Latest Publications
- 18 November 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
Distinguishing Major Forms of Dementia Through Neuropsychological Performances: A Systematic Review With Structured Narrative Synthesis
Objective: Major dementia subtypes show characteristic neurocognitive profiles, but findings vary across neuropsychological tests, diagnostic frameworks, disease severity, and assessment languages. This systematic review examined whether subtype-level profiles remain consistent despite methodological and clinical heterogeneity. Methods: Web of Science, PubMed, Scopus, and APA PsycArticles were searched on December 31, 2025, for English-language articles published from 2015 onward comparing AD, bvFTD, DLB, or VaD with non-dementia controls using validated neuropsychological tests. Effect sizes were synthesized across general intelligence, executive function, social cognition, attention/processing-speed, verbal function, visuospatial function, and episodic memory. Results: Of 14 175 records, 116 studies were included. Effect size magnitude varied according to task demands and scoring methods and was discussed in the context of methodological and clinical sources of heterogeneity. Conclusion: Synthesizing effect sizes enabled comparison across diverse neuropsychological tests, demonstrating that domain-level cognitive profiles were more robust than individual test findings, supporting profile-based neuropsychological interpretation.
- 18 November 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
Distinguishing Major Forms of Dementia Through Neuropsychological Performances: A Systematic Review With Structured Narrative Synthesis
Objective: Major dementia subtypes show characteristic neurocognitive profiles, but findings vary across neuropsychological tests, diagnostic frameworks, disease severity, and assessment languages. This systematic review examined whether subtype-level profiles remain consistent despite methodological and clinical heterogeneity. Methods: Web of Science, PubMed, Scopus, and APA PsycArticles were searched on December 31, 2025, for English-language articles published from 2015 onward comparing AD, bvFTD, DLB, or VaD with non-dementia controls using validated neuropsychological tests. Effect sizes were synthesized across general intelligence, executive function, social cognition, attention/processing-speed, verbal function, visuospatial function, and episodic memory. Results: Of 14 175 records, 116 studies were included. Effect size magnitude varied according to task demands and scoring methods and was discussed in the context of methodological and clinical sources of heterogeneity. Conclusion: Synthesizing effect sizes enabled comparison across diverse neuropsychological tests, demonstrating that domain-level cognitive profiles were more robust than individual test findings, supporting profile-based neuropsychological interpretation.
- 6 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Groaning in Progressive Supranuclear Palsy: Insights From a Large Asian Cohort
Background: Although regularly encountered, the groaning phenomenon in progressive supranuclear palsy (PSP) currently lacks systematic investigation. Objectives: We investigated the frequency and clinical phenomenology of groaning in PSP. Methods: We assessed 180 patients with PSP, identifying groaning through examination and history. A specially designed questionnaire captured groaning characteristics (intensity, frequency, and triggers). Scores for the PSP Clinical Deficits Scale (PSP‐CDS), Barthel Index (BI), Short Cognitive and Neuropsychiatric Assessment (ShoCo) Scale, and modified Zarit Burden Interview (ZBI), and whole exome sequencing (WES) data, were extracted from our research database. Results: Thirty‐six (20.0%) patients exhibited groaning, most of whom (77.8%) had Richardson's syndrome (PSP‐RS), which predicted groaning with an odds ratio (OR) of 4.1 (95% CI = 1.7–10.3, P = 0.002). Worse disease severity (PSP‐CDS) was also a predictive factor (OR = 1.2, 95% CI = 1.1–1.3, P = 0.002). Additionally, patients with groaning demonstrated worse longitudinal disease trajectory, alongside significantly greater functional disability (BI), cognitive‐behavioral impairment (ShoCo), and caregiver burden (ZBI). Groaning was typically moderate in intensity or loud, considered troublesome by caregivers and/or patients, and triggers or reasons were commonly identified (in 76.0%). WES showed several patients carrying pathogenic/likely pathogenic variants in genes potentially relevant to PSP ( MAPT , GBA1 , and SMPD1 ), but none carried the rare NEFH variant previously linked to familial moaning (p.Ile245Met). Conclusions: Our study provides insights into a poorly understood feature of PSP and highlights a troublesome symptom that is associated with substantial patient and caregiver burden. Further work is needed to investigate the pathophysiological basis of groaning and to develop effective therapies for it.
- 6 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Groaning in Progressive Supranuclear Palsy: Insights From a Large Asian Cohort
Background: Although regularly encountered, the groaning phenomenon in progressive supranuclear palsy (PSP) currently lacks systematic investigation. Objectives: We investigated the frequency and clinical phenomenology of groaning in PSP. Methods: We assessed 180 patients with PSP, identifying groaning through examination and history. A specially designed questionnaire captured groaning characteristics (intensity, frequency, and triggers). Scores for the PSP Clinical Deficits Scale (PSP‐CDS), Barthel Index (BI), Short Cognitive and Neuropsychiatric Assessment (ShoCo) Scale, and modified Zarit Burden Interview (ZBI), and whole exome sequencing (WES) data, were extracted from our research database. Results: Thirty‐six (20.0%) patients exhibited groaning, most of whom (77.8%) had Richardson's syndrome (PSP‐RS), which predicted groaning with an odds ratio (OR) of 4.1 (95% CI = 1.7–10.3, P = 0.002). Worse disease severity (PSP‐CDS) was also a predictive factor (OR = 1.2, 95% CI = 1.1–1.3, P = 0.002). Additionally, patients with groaning demonstrated worse longitudinal disease trajectory, alongside significantly greater functional disability (BI), cognitive‐behavioral impairment (ShoCo), and caregiver burden (ZBI). Groaning was typically moderate in intensity or loud, considered troublesome by caregivers and/or patients, and triggers or reasons were commonly identified (in 76.0%). WES showed several patients carrying pathogenic/likely pathogenic variants in genes potentially relevant to PSP ( MAPT , GBA1 , and SMPD1 ), but none carried the rare NEFH variant previously linked to familial moaning (p.Ile245Met). Conclusions: Our study provides insights into a poorly understood feature of PSP and highlights a troublesome symptom that is associated with substantial patient and caregiver burden. Further work is needed to investigate the pathophysiological basis of groaning and to develop effective therapies for it.
- Open Access
The Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) tracks longitudinal progression in PSP
Background: The Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) is a brief rating scale of clinical severity in PSP. However, its longitudinal performance has not been evaluated. We aimed to assess the ability of the PSP-CDS to track disease progression over time and to compare progression across PSP phenotypes in a real-world Asian cohort. Methods: Patients who met the Movement Disorder Society PSP diagnostic criteria and underwent at least 2 PSP-CDS assessments were recruited from movement disorders clinics in Malaysia. Longitudinal progression was evaluated using linear mixed-effects models. Domain-specific progression and subtype-specific trajectories were also analyzed. Associations between annualized changes in PSP-CDS and Barthel Index (BI) scores were examined. Results: 104 patients (including 59 with PSP-Richardson's syndrome [PSP-RS], 28 with predominant parkinsonism [PSP-P], and 14 with progressive gait freezing [PSP-PGF]) contributed 394 PSP-CDS assessments over a median follow-up of 33.2 months (range, 8.7-73.1 months). PSP-CDS scores increased significantly over time (β=0.126 points/month), corresponding to estimated increases of 1.13 points over 9 months and 2.27 points over 18 months. Subtype-specific analyses demonstrated the fastest progression in PSP-RS (0.156 points/month), followed by PSP-PGF (0.081 points/month) and PSP-P (0.077 points/month). Exploratory domain-level analyses showed that finger dexterity, communication, and dysphagia were the most rapidly worsening domains. Annualized PSP-CDS progression correlated significantly with annualized decline in BI scores (Spearman's ρ=-0.474, P<0.001). Conclusions: The PSP-CDS is sensitive to longitudinal disease progression in PSP and captures clinically-meaningful functional decline. Its brevity and ability to distinguish differential progression across PSP phenotypes support its utility as a pragmatic outcome measure for routine clinical practice and research.
Open AccessThe Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) tracks longitudinal progression in PSP
Background: The Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) is a brief rating scale of clinical severity in PSP. However, its longitudinal performance has not been evaluated. We aimed to assess the ability of the PSP-CDS to track disease progression over time and to compare progression across PSP phenotypes in a real-world Asian cohort. Methods: Patients who met the Movement Disorder Society PSP diagnostic criteria and underwent at least 2 PSP-CDS assessments were recruited from movement disorders clinics in Malaysia. Longitudinal progression was evaluated using linear mixed-effects models. Domain-specific progression and subtype-specific trajectories were also analyzed. Associations between annualized changes in PSP-CDS and Barthel Index (BI) scores were examined. Results: 104 patients (including 59 with PSP-Richardson's syndrome [PSP-RS], 28 with predominant parkinsonism [PSP-P], and 14 with progressive gait freezing [PSP-PGF]) contributed 394 PSP-CDS assessments over a median follow-up of 33.2 months (range, 8.7-73.1 months). PSP-CDS scores increased significantly over time (β=0.126 points/month), corresponding to estimated increases of 1.13 points over 9 months and 2.27 points over 18 months. Subtype-specific analyses demonstrated the fastest progression in PSP-RS (0.156 points/month), followed by PSP-PGF (0.081 points/month) and PSP-P (0.077 points/month). Exploratory domain-level analyses showed that finger dexterity, communication, and dysphagia were the most rapidly worsening domains. Annualized PSP-CDS progression correlated significantly with annualized decline in BI scores (Spearman's ρ=-0.474, P<0.001). Conclusions: The PSP-CDS is sensitive to longitudinal disease progression in PSP and captures clinically-meaningful functional decline. Its brevity and ability to distinguish differential progression across PSP phenotypes support its utility as a pragmatic outcome measure for routine clinical practice and research.
- Open Access
- 7 June 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 814-823
Longitudinal Neurocognitive Changes for Patients With Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review With Structured Narrative Synthesis
Objectives: Neurocognitive changes in hematological malignancies (HM) and as a sequela of hematopoietic stem cell transplantation (HSCT) remain under‐recognized. These changes may substantially affect patients' quality of life. Therefore, this review systematically evaluated longitudinal neurocognitive changes in patients with HM undergoing HSCT. Methods: Following PRISMA guidelines, PubMed, Scopus, and CINAHL were searched on October 30, 2025. Longitudinal studies assessing neurocognitive changes in patients with HM undergoing HSCT, with or without healthy controls, were included. Risk of bias was assessed using an adapted National Institutes of Health quality assessment tool for before–after studies. Effect sizes with 95% confidence intervals were calculated to quantify changes in neurocognitive performance. Results: Nine of 2012 studies met the inclusion criteria, with overall moderate study quality. Improvements may occur post‐HSCT; however, allogeneic HSCT and myeloablative conditioning were main risk factors identified for persistent cognitive decline. In line with white matter damage, executive function and attention/processing speed impairments likely represent core deficits, which may affect other cognitive impairments. Post‐HSCT changes depend on task characteristics, cognitive load, and conditioning intensity. Conclusions: Future research should emphasize regular neurocognitive assessment to guide cognitive rehabilitation, implement pre‐transplant cognitive rehabilitation strategies to mitigate post‐HSCT cognitive decline, and enhance treatment outcomes.
- 7 June 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 814-823
Open AccessLongitudinal Neurocognitive Changes for Patients With Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review With Structured Narrative Synthesis
Objectives: Neurocognitive changes in hematological malignancies (HM) and as a sequela of hematopoietic stem cell transplantation (HSCT) remain under‐recognized. These changes may substantially affect patients' quality of life. Therefore, this review systematically evaluated longitudinal neurocognitive changes in patients with HM undergoing HSCT. Methods: Following PRISMA guidelines, PubMed, Scopus, and CINAHL were searched on October 30, 2025. Longitudinal studies assessing neurocognitive changes in patients with HM undergoing HSCT, with or without healthy controls, were included. Risk of bias was assessed using an adapted National Institutes of Health quality assessment tool for before–after studies. Effect sizes with 95% confidence intervals were calculated to quantify changes in neurocognitive performance. Results: Nine of 2012 studies met the inclusion criteria, with overall moderate study quality. Improvements may occur post‐HSCT; however, allogeneic HSCT and myeloablative conditioning were main risk factors identified for persistent cognitive decline. In line with white matter damage, executive function and attention/processing speed impairments likely represent core deficits, which may affect other cognitive impairments. Post‐HSCT changes depend on task characteristics, cognitive load, and conditioning intensity. Conclusions: Future research should emphasize regular neurocognitive assessment to guide cognitive rehabilitation, implement pre‐transplant cognitive rehabilitation strategies to mitigate post‐HSCT cognitive decline, and enhance treatment outcomes.
- 27 March 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (3) , 638-660
Music‐based intervention as an adjunctive therapy in people with epilepsy: A scoping review
Epilepsy is a major neurological disorder that affects individuals across all age groups and can significantly impair their quality of life. Although pharmacological treatments are available, there remains a need for complementary non‐pharmacological lifestyle interventions. Music‐based intervention (MBI) is a possible option, as it is non‐invasive, cost‐effective, and easily implemented. This scoping review aims to identify and describe MBIs used in the management of epilepsy. A systematic search was conducted from April 9 to June 10, 2025, using two electronic databases: Ovid Medline and Scopus. The protocol was prospectively registered with the Research Ethics Committee of Universiti Kebangsaan Malaysia (FF‐2025‐173) and PROSPERO (CRD420251119617). Of the 3977 articles identified, 21 studies investigating MBIs for epilepsy met the inclusion criteria. Ten studies were rated as having a high risk of bias based on the Cochrane risk‐of‐bias assessment tool. The remaining studies provided Class II evidence according to both the GRADE and OCEBM frameworks. Most studies used passive listening of pre‐recorded Mozart K.448 for intervention. Overall, MBIs were assigned a Level C recommendation for epilepsy. MBIs for epilepsy require further investigations with robust study designs and a standardized protocol. Heterogeneous study designs and small samples are likely barriers to meaningful clinical translation. Therefore, the rating of recommendations only serves as a point of reference. Future avenues include live performance and reminiscence elements.
- 27 March 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (3) , 638-660
Music‐based intervention as an adjunctive therapy in people with epilepsy: A scoping review
Epilepsy is a major neurological disorder that affects individuals across all age groups and can significantly impair their quality of life. Although pharmacological treatments are available, there remains a need for complementary non‐pharmacological lifestyle interventions. Music‐based intervention (MBI) is a possible option, as it is non‐invasive, cost‐effective, and easily implemented. This scoping review aims to identify and describe MBIs used in the management of epilepsy. A systematic search was conducted from April 9 to June 10, 2025, using two electronic databases: Ovid Medline and Scopus. The protocol was prospectively registered with the Research Ethics Committee of Universiti Kebangsaan Malaysia (FF‐2025‐173) and PROSPERO (CRD420251119617). Of the 3977 articles identified, 21 studies investigating MBIs for epilepsy met the inclusion criteria. Ten studies were rated as having a high risk of bias based on the Cochrane risk‐of‐bias assessment tool. The remaining studies provided Class II evidence according to both the GRADE and OCEBM frameworks. Most studies used passive listening of pre‐recorded Mozart K.448 for intervention. Overall, MBIs were assigned a Level C recommendation for epilepsy. MBIs for epilepsy require further investigations with robust study designs and a standardized protocol. Heterogeneous study designs and small samples are likely barriers to meaningful clinical translation. Therefore, the rating of recommendations only serves as a point of reference. Future avenues include live performance and reminiscence elements.
- 10 July 2025
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 55 (2) , 150-160
Group Live Music Reminiscence Therapy for People with Dementia: A Mixed-Method Systematic Review
Introduction: Group music reminiscence therapy is often a preferred option for people with dementia owing to its efficacy in evoking autobiographical memories. Live music performances may further enhance interpersonal connections and social relationships, leading to a more meaningful participation. While an updated review on the efficacy of group music reminiscence therapy was published recently, only studies with pre-recorded music were included. Methods: This systematic review focused on the effects of group live music reminiscence therapy on the cognition, behavioural and psychological symptoms, and quality of life of people with dementia. We conducted the initial search on September 1, 2024, following the PRISMA guidelines using PubMed and Scopus. We then reran searches prior to the final analysis on March 20, 2025. We assessed the risk of bias using Cochrane Collaboration’s tool and assigned level of recommendations according to the American Academy of Neurology guideline. Results: Of 1,846 articles, six studies involving 330 people with dementia and 10 caregivers were included. We assigned Level B recommendations for depression and anxiety in people with dementia. Findings on cognition, other behavioural and psychological symptoms, and quality of life were either limited or preliminary. Four studies reported qualitative findings and were synthesised into the following themes: (1) psychological well-being and improvements in mood; (2) engagement and participation. Conclusion: Studies on group live music reminiscence therapy showed beneficial effects on depression and anxiety symptoms in people with dementia, while evidence for managing agitation and wandering, and improving the quality of life of people with dementia remains scarce and generally inconclusive. This warrants further investigation for meaningful clinical translation.
- 10 July 2025
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 55 (2) , 150-160
Group Live Music Reminiscence Therapy for People with Dementia: A Mixed-Method Systematic Review
Introduction: Group music reminiscence therapy is often a preferred option for people with dementia owing to its efficacy in evoking autobiographical memories. Live music performances may further enhance interpersonal connections and social relationships, leading to a more meaningful participation. While an updated review on the efficacy of group music reminiscence therapy was published recently, only studies with pre-recorded music were included. Methods: This systematic review focused on the effects of group live music reminiscence therapy on the cognition, behavioural and psychological symptoms, and quality of life of people with dementia. We conducted the initial search on September 1, 2024, following the PRISMA guidelines using PubMed and Scopus. We then reran searches prior to the final analysis on March 20, 2025. We assessed the risk of bias using Cochrane Collaboration’s tool and assigned level of recommendations according to the American Academy of Neurology guideline. Results: Of 1,846 articles, six studies involving 330 people with dementia and 10 caregivers were included. We assigned Level B recommendations for depression and anxiety in people with dementia. Findings on cognition, other behavioural and psychological symptoms, and quality of life were either limited or preliminary. Four studies reported qualitative findings and were synthesised into the following themes: (1) psychological well-being and improvements in mood; (2) engagement and participation. Conclusion: Studies on group live music reminiscence therapy showed beneficial effects on depression and anxiety symptoms in people with dementia, while evidence for managing agitation and wandering, and improving the quality of life of people with dementia remains scarce and generally inconclusive. This warrants further investigation for meaningful clinical translation.
- Open Access
- 17 August 2024
- Published by Wiley in Aging Medicine
- Vol. 7 (4) , 528-534
The effectiveness of group music reminiscence therapy for people thriving with dementia: A systematic review of randomized controlled trials
Dementia is characterized by a progressive decline in cognition, behavioral and psychological symptoms (BPSD), and quality of life (QoL). The lack of curative therapies has led to a psychosocial discourse prioritizing QoL of people thriving with dementia (PTD). Group reminiscence therapy (RT) is a relatively inexpensive intervention, with music prompts being a preferred choice, owing to robust musical memory in the early disease stage. However, a synthesis of current evidence is needed to inform research and clinical use of group music RT in dementia care. Therefore, we conducted a systematic review on PubMed, Scopus, CINAHL, APA PsycInfo, and APA PsycArticles to critically appraise published randomized controlled trials examining group music RT to improve cognition, BPSD, and QoL in PTD. Of 14,725 articles, two RCTs involving 102 PTD were included. All studies used prerecorded music for group music RT. All studies were deemed of good quality, adhering to intention‐to‐treat analysis and assessor blinding. Based on the American Academy of Neurology guidelines, we assigned a Level C recommendation for group music RT for cognition and Level B recommendations for BPSD and QoL (ineffective). In conclusion, group music RT may be useful for symptomatic management in PTD. However, heterogeneous study designs, disease severity, dementia subtype, and outcome measures are likely barriers to meaningful clinical translation. Therefore, the rating of recommendations only serves as a point of reference. Future avenues include live performances as prompts for group music RT.
- 17 August 2024
- Published by Wiley in Aging Medicine
- Vol. 7 (4) , 528-534
Open AccessThe effectiveness of group music reminiscence therapy for people thriving with dementia: A systematic review of randomized controlled trials
Dementia is characterized by a progressive decline in cognition, behavioral and psychological symptoms (BPSD), and quality of life (QoL). The lack of curative therapies has led to a psychosocial discourse prioritizing QoL of people thriving with dementia (PTD). Group reminiscence therapy (RT) is a relatively inexpensive intervention, with music prompts being a preferred choice, owing to robust musical memory in the early disease stage. However, a synthesis of current evidence is needed to inform research and clinical use of group music RT in dementia care. Therefore, we conducted a systematic review on PubMed, Scopus, CINAHL, APA PsycInfo, and APA PsycArticles to critically appraise published randomized controlled trials examining group music RT to improve cognition, BPSD, and QoL in PTD. Of 14,725 articles, two RCTs involving 102 PTD were included. All studies used prerecorded music for group music RT. All studies were deemed of good quality, adhering to intention‐to‐treat analysis and assessor blinding. Based on the American Academy of Neurology guidelines, we assigned a Level C recommendation for group music RT for cognition and Level B recommendations for BPSD and QoL (ineffective). In conclusion, group music RT may be useful for symptomatic management in PTD. However, heterogeneous study designs, disease severity, dementia subtype, and outcome measures are likely barriers to meaningful clinical translation. Therefore, the rating of recommendations only serves as a point of reference. Future avenues include live performances as prompts for group music RT.
- 7 August 2024
- Published by Springer Nature in Current Psychology
- Vol. 43 (34) , 27423-27436
What was done for young people aged 10 to 24 in Singapore? A systematic review on mental health interventions
- 7 August 2024
- Published by Springer Nature in Current Psychology
- Vol. 43 (34) , 27423-27436
What was done for young people aged 10 to 24 in Singapore? A systematic review on mental health interventions